Trial Profile
A Phase II Study of Pazopanib in VEGF-TKI Refractory Metastatic Renal Cell Carcinoma (MRCC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 20 Jun 2021 Status changed from active, no longer recruiting to completed.
- 08 Mar 2021 Planned End Date changed from 31 Jan 2021 to 31 Dec 2021.
- 08 Mar 2021 Planned primary completion date changed from 31 Jan 2021 to 31 Dec 2021.